论文部分内容阅读
目的:观察小剂量顺铂联合变异LV5FU2(Lc-LV5FU2)治疗进展期胃癌的疗效。方法:60例进展期胃癌随机分为观察组(Lc-LV5FU2)和对照组(FOLFOX4),就其有效率、临床受益反应率、毒性和QOL评分改善率进行比较。结果:观察组和对照组的RR(42%vs46·6%),CBR(84%vs85·6%),QOL评分改善率(25%vs22%)的差异无统计学意义。P值均>0·05。两组的毒性反应为恶心呕吐、白细胞减少和外周神经毒性,但多轻微。结论:小剂量顺铂联合变异LV5FU2方案治疗进展期胃癌有效、安全,毒副作用可耐受,且价格较低,是一个有价值的方案。
Objective: To observe the curative effect of low-dose cisplatin combined with mutant LV5FU2 (Lc-LV5FU2) on advanced gastric cancer. Methods: Sixty patients with advanced gastric cancer were randomly divided into observation group (Lc-LV5FU2) and control group (FOLFOX4), and their efficiency, clinical benefit response rate, toxicity and QOL score improvement rate were compared. Results: There was no significant difference between the observation group and the control group in RR (42% vs 46.6%), CBR (84% vs 85.6%), QOL improvement (25% vs 22%). P values were all> 0 · 05. Toxicities in both groups were nausea and vomiting, leukopenia and peripheral neurotoxicity, but more often than not. CONCLUSIONS: Low-dose cisplatin combined with variant LV5FU2 regimen is an effective and safe treatment for advanced gastric cancer and its toxicity and side effects are tolerable and low in price. It is a valuable solution.